Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

20.37 +0.76 (+3.88%)
Streaming Delayed Price Updated: 3:16 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 111,957
Open 19.61
Bid (Size) 20.37 (2)
Ask (Size) 20.41 (3)
Prev. Close 19.61
Today's Range 19.61 - 20.67
52wk Range 9.260 - 26.70
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
From Castle Biosciences Inc.
Via Business Wire

Performance

YTD
-7.24%
-7.24%
1 Month
-2.16%
-2.16%
3 Month
+2.93%
+2.93%
6 Month
+59.14%
+59.14%
1 Year
-14.27%
-14.27%

More News

Read More
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Recap: Castle Biosciences Q4 Earnings
Via Benzinga
Earnings Preview For Castle Biosciences
Via Benzinga
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Updates to its Board of Directors
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
From Castle Biosciences Inc.
Via Business Wire
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
From Castle Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
From Castle Biosciences Inc.
Via Business Wire
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.